General Anesthesia Drugs Market - Growth, Trends , COVID-19 Impact, and Forecasts 2019 – 2027

The general anesthesia drugs market is segmented By Drug Type (Propofol, Sevoflurane, Dexmedetomidine, Desflurane, Remifentanil, Midazolam, Other General Anesthesia Drugs), By Route of Administration (Inhalation and intravenous) and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The report offers the value (in USD million) for the above segments.

Overview of the Market

During the forecast period, the General Anesthesia Drugs Market is expected to grow at a CAGR of 3.68 percent.

There is a small decrease in demand for general anaesthetics during the COVID 19 epidemic. This is because regional anaesthesia, including caesarean sections, is favoured over general anaesthetic. The market was particularly influenced by the difficulties that arose as a result of the pandemic's interruption of manufacturing and supply chains. Non-essential surgical procedures have also been halted in order to prepare for an expected increase in COVID-19-related inpatient hospital admissions and to prevent the virus from spreading within health-care facilities. The need for surgical anaesthetics has reduced as a result of the decline in non-essential procedures.

The rise in the number of cardiovascular disorders and an increase in the senior population in industrialised countries are two variables that contribute to the growth of general anaesthesia. Cardiovascular disease (CVD) is the largest cause of death worldwide, and the majority of CVD patients require surgery. General anaesthesia is administered before to surgery. General anesthesia's primary purpose is to render the patient unconscious and numb to pain during the surgical process.

According to the Centers for Disease Control and Prevention (CDC), there will be 360,900 deaths in the United States related to coronary heart disease in 2019. The most frequent type of cardiovascular disease is coronary artery disease. According to the CDC, almost 18.2 million persons in the United States have coronary artery disease.

Furthermore, according to the World Health Organization, there will be 17.9 million deaths worldwide related to cardiovascular disease (CVD) in 2019, accounting for almost 32% of all deaths. According to the same source, low- and middle-income countries account for more than 75% of all deaths. According to articles published in the Journal of the American College of Cardiology, global CVD prevalence has doubled from 271 million in 1990 to 523 million in 2019, and the number of CVD-related deaths has steadily increased from 12.1 million in 1990 to 18.6 million in 2019. As a result, as the prevalence of CVD rises, so does the number of surgical procedures, boosting the demand for general anaesthetic pharmaceuticals.